Bilimetrix s.r.l. is a R&D Biomed company who launched on the international market “Bilistick® System”, an in vitro Point of Care (POC) system for early diagnosis of hyperbilirubinemia. Bilistick is the only in vitro rapid diagnostic for measuring the level of bilirubin in newborns blood. It is the result of experience acquired during years of academic and professional research carried out by its entrepreneurial team.  
	Bilistick® is used as a screening diagnostic to estimate the plasma total bilirubin concentration, triage newborns and evaluate risk of hyperbilirubinemia during discharge from birthing centres and to assess severity of jaundice in newborns during follow up visits. In developing countries, where bilirubin-induced brain injury is common and laboratory resources for rapid bilirubin assays are often unavailable, Bilistick® serve a critical need to guide treatment decisions of jaundiced newborns.
We envision a world free from kernicterus, a preventable disabling condition, allowing newborns to survive and enjoy a healthy life. 
The mission of our company is to provide key stakeholders with low cost and effective solutions to monitor neonatal jaundice and prevent kernicterus. We expect to benefit hospitals and doctors in western countries and health care workers, governments and humanitarian organizations in developing countries with useful tools for appropriate neonatal jaundice management.


Bilimetrix s.r.l.

Org chart

Teams

Offices

Bilimetrix s.r.l.

Org chart

Teams

Offices

Related companies